Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track COLL with free AI briefings, catalyst countdowns, and dilution alerts.

COLL · COLLEGIUM PHARMACEUTICAL, INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$129.5M Cash on Hand

CF+ Cash Runway

Follow COLL by email Get an email when COLL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about COLL, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Dec 2026 · Phase 4 · Upcoming Trial · Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS
Registry primary completion date, not a results date
Dec 2025 · N/A · Recruiting · Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Oxycodone FDA approved Apr 2016 · Xtampza Er	Chronic Pain	Phase 4 · NCT03588806	Terminated
Ticagrelor	Unstable Angina Pectoris	Phase 4 · NCT02939248	Completed
Morphine	Unstable Angina	Phase 4 · NCT04442919	Completed
Methoxyflurane	Unstable Angina	Phase 4 · NCT04442919	Completed
Rosuvastatin	Hypercholesterolemia	Phase 4 · NCT02772640	Completed
Levosimendan	Systolic Heart Failure	Phase 4 · NCT03764722	Unknown
Delayed-release, extended-release methyl	ADHD	Phase 4 · NCT07838311	Not yet recruiting
Switch to prasugrel 5 mg at day 45	Non ST Segment Elevation Acute Coronary Syndrome	Phase 3 · NCT05779059	Unknown
De-escalation to prasugrel 5 mg at day 3	Non ST Segment Elevation Acute Coronary Syndrome	Phase 3 · NCT05779059	Unknown
De-escalation to ticagrelor 60 mg at day	Non ST Segment Elevation Acute Coronary Syndrome	Phase 3 · NCT05779059	Unknown
Switch to ticagrelor 60 mg at day 45	Non ST Segment Elevation Acute Coronary Syndrome	Phase 3 · NCT05779059	Unknown
Oxycodone DETERx	Chronic Low Back Pain	Phase 3 · NCT01685684	Completed
Methoxyflurane - Penthrox	ST Elevation Myocardial Infarction	Phase 3 · NCT04476173	Unknown
Methylphenidate	Attention Deficit Hyperactivity Disorder	Phase 3 · NCT06431256	Terminated

Also used in these trials (approved or third-party drugs, not COLL's own candidates): Rifaximin, Aspirin, Empagliflozin, Evolocumab, Prasugrel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

COLL holds $129.5M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Recent financing filings on SEC EDGAR:

Dec 30, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COLL files for a raise →

Get the full COLL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COLL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z